Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02142049 · ClinicalTrials.gov registry record · Phase 1
Ibrutinib and Lenalidomide With Dose Adjusted EPOCH-R in Subjects With Relapsed/Refractory Diffuse Large B-cell Lymphoma
A Phase 1 study, sponsored by Pharmacyclics.
- Completed
- Registry status
- Phase 1
- Development phase
- 35
- Enrollment target
NCT02142049 is a Phase 1 study that has completed, run by Pharmacyclics. The registered enrollment target is 35 participants.
The verdict
NCT02142049, a Phase 1 study, has completed, sponsored by Pharmacyclics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 35 participants
- Enrollment target
Study Summary
This is a Phase 1b/2, open-label, non-randomized multicenter study to assess the safety and efficacy of ibrutinib and lenalidomide in combination with DA-EPOCH-R in subjects with relapsed/refractory Diffuse Large B-cell Lymphoma (DLBCL).
Interventions
- DRUG Lenalidomide
- DRUG Ibrutinib
- DRUG DA-EPOCH-R
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 35 participants |
| Start Date | 2014-05 |
| Est. Completion | 2017-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02142049
The ClinicalTrials.gov registry entry for NCT02142049 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 35 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pharmacyclics, which has 54 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Lenalidomide is the first listed.
NCT02142049 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02142049 about?
NCT02142049 is a clinical study titled "Ibrutinib and Lenalidomide With Dose Adjusted EPOCH-R in Subjects With Relapsed/Refractory Diffuse Large B-cell Lymphoma". This is a Phase 1b/2, open-label, non-randomized multicenter study to assess the safety and efficacy of ibrutinib and lenalidomide in combination with DA-EPOCH-R in subjects with relapsed/refractory Diffuse Large B-cell Lymphoma (DLBCL).
What is the current status of trial NCT02142049?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 35 participants. The study started on 2014-05. Estimated completion is 2017-08.
What interventions are being tested in trial NCT02142049?
The interventions under investigation include: Lenalidomide (DRUG), Ibrutinib (DRUG), DA-EPOCH-R (DRUG).
Who is sponsoring clinical trial NCT02142049?
This trial is sponsored by Pharmacyclics, which has 54 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.